preprints.org > chemistry and materials science > nanotechnology > doi: 10.20944/preprints202301.0053.v1

Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Version 1 : Received: 31 December 2022 / Approved: 4 January 2023 / Online: 4 January 2023 (03:19:26 CET)

Advances in nanomedicine bring the attention of researchers to the molecular targets which can play a major role in the development of novel therapeutic and diagnostic modalities for cancer management. The choice of a proper molecular target can decide on the efficacy of the treatment and endorse the personalized medicine approach. Gastrin-releasing peptide receptor (GRPR) is a G-protein-coupled membrane receptor, well known to be overexpressed in numerous malignancies including pancreatic, prostate, breast, lung, colon, cervical and gastrointestinal cancers. Therefore, many research groups express a deep interest in targeting GRPR with their nanoformulations. A broad spectrum of the GRPR ligands has been described in the literature, which allows tuning of the properties of the final formulation, particularly in the field of the ligand affinity to the receptor and internalization possibilities. Hereby the recent advances in the field of applications of various nanoplatforms which are able to reach the GRPR expressing cells are reviewed.

gastrin releasing peptide receptor; GRPR; bombesin receptor subtype 2; BB2; bombesin; targeted therapy; molecular imaging; theranostics; nanotechnology; nanoparticle; nanomedicine

Chemistry and Materials Science, Nanotechnology

* All users must log in before leaving a comment